Optimizing maternal and neonatal outcomes through tight control management of inflammatory bowel disease during pregnancy: a pilot feasibility study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 05 2023
Historique:
received: 24 03 2022
accepted: 16 05 2023
medline: 24 5 2023
pubmed: 23 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

A home point-of care FCP test (IBDoc) and a self-reported clinical disease activity program (IBD Dashboard) may improve routine monitoring of IBD activity during pregnancy. We aimed to evaluate the feasibility of tight control management using remote monitoring in pregnant patients with IBD. Pregnant patients (< 20 weeks) with IBD were prospectively enrolled from Mount Sinai Hospital between 2019 and 2020. Patients completed the IBDoc and IBD Dashboard at three core time points. Disease activity was measured clinically using the Harvey-Bradshaw Index (mHBI) for CD and partial Mayo (pMayo) for UC, or objectively using FCP. A feasibility questionnaire was completed in the third trimester. Seventy-seven percent of patients (24 of 31) completed the IBDoc and IBD Dashboard at all core time points. Twenty-four patients completed the feasibility questionnaires. All survey respondents strongly preferred using the IBDoc over standard lab-based testing and would use the home kit in the future. Exploratory analysis identified discordance rates of more than 50% between clinical and objective disease activity. Tight control management using remote monitoring may be feasible among pregnant patients with IBD. A combination of both clinical scores and objective disease markers may better predict disease activity.

Identifiants

pubmed: 37217778
doi: 10.1038/s41598-023-35332-z
pii: 10.1038/s41598-023-35332-z
pmc: PMC10202356
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8291

Informations de copyright

© 2023. The Author(s).

Références

Can J Gastroenterol. 2012 Nov;26(11):811-7
pubmed: 23166905
Inflamm Bowel Dis. 2014 Dec;20(12):2276-85
pubmed: 25248002
Gut. 2010 Dec;59(12):1652-61
pubmed: 21071584
Can J Gastroenterol Hepatol. 2016;2016:2483261
pubmed: 27774443
Inflamm Bowel Dis. 2017 Jun;23(6):894-902
pubmed: 28511198
Inflamm Bowel Dis. 2014 Oct;20(10):1761-9
pubmed: 25159453
Inflamm Bowel Dis. 2019 Mar 14;25(4):627-641
pubmed: 30821832
Inflamm Bowel Dis. 2011 Jun;17(6):1270-6
pubmed: 21560190
BJOG. 2016 Oct;123(11):1862-70
pubmed: 26924786
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
Inflamm Bowel Dis. 2016 Mar;22(3):623-30
pubmed: 26829408
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
JGH Open. 2019 Mar 18;3(4):302-309
pubmed: 31406923
Inflamm Bowel Dis. 2017 Jun;23(6):1011-1018
pubmed: 28346274
Dig Dis Sci. 2018 May;63(5):1294-1301
pubmed: 29468374
Clin Chem Lab Med. 2010 Feb;48(2):237-48
pubmed: 19943809
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):926-931
pubmed: 29240011
J Crohns Colitis. 2019 Mar 30;13(4):424-430
pubmed: 30445625
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Clin Gastroenterol Hepatol. 2016 Sep;14(9):1285-1292.e1
pubmed: 27001269
J Crohns Colitis. 2016 Sep;10(9):1103-21
pubmed: 26928960
Gut. 2007 Jun;56(6):830-7
pubmed: 17185356
Turk J Gastroenterol. 2017 May;28(3):171-175
pubmed: 28336498
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24
pubmed: 22344983
Inflamm Bowel Dis. 2017 Jul;23(7):1240-1246
pubmed: 28498159
J Crohns Colitis. 2015 Jul;9(7):519-24
pubmed: 25939352
Dig Dis Sci. 2021 May;66(5):1639-1649
pubmed: 32533542
Eur J Intern Med. 2020 Jul;77:105-110
pubmed: 32197833
J Reprod Med. 2010 Mar-Apr;55(3-4):115-23
pubmed: 20506671
J Clin Gastroenterol. 2019 Sep;53(8):574-581
pubmed: 31306343
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16
pubmed: 31294381
Gastroenterology. 2017 Feb;152(3):554-563.e9
pubmed: 27773807
Dig Dis Sci. 2022 Sep;67(9):4269-4277
pubmed: 33939151
Gastroenterology. 2016 Mar;150(3):734-757.e1
pubmed: 26688268
Clin Transl Gastroenterol. 2018 Feb 20;9(3):136
pubmed: 29491393
Inflamm Bowel Dis. 2019 May 4;25(6):1107-1114
pubmed: 30535387
Inflamm Bowel Dis. 2017 Sep;23(9):1600-1604
pubmed: 28590341
Inflamm Bowel Dis. 2014 Apr;20(4):742-56
pubmed: 24562174

Auteurs

Rohit Jogendran (R)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada.

Katie O'Connor (K)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada.

Ajani Jeyakumar (A)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada.

Parul Tandon (P)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada.

Geoffrey C Nguyen (GC)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada.

Cynthia Maxwell (C)

Division of Maternal Fetal Medicine, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, Toronto, ON, Canada.
Women's College Hospital Research Institute, Women's College Hospital, Toronto, ON, Canada.

Vivian Huang (V)

Division of Gastroenterology and Hepatology, IBD Clinical Research Program, Mount Sinai Hospital, Sinai Health System, University of Toronto, Suite 441 - 600 University Avenue, Toronto, ON, M5G 1X5, Canada. Vivian.Huang@sinaihealth.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH